European Commission grants conditional approval for Lytgobi to treat cholangiocarcinoma – Taiho Oncology Europe
Taiho Pharmaceutical and its subsidiary Taiho Oncology Europe have received conditional marketing authorisation from the European Commission for Lytgobi (futibatinib) tablets to treat adults with cholangiocarcinoma (CCA). The… read more.
